The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve

Sponsor
Women's Hospital School Of Medicine Zhejiang University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06081257
Collaborator
(none)
80
2
8.7

Study Details

Study Description

Brief Summary

"KB-120" small molecular nutrient is a structural multi-molecular natural nutrient with different components. It is produced from strains and natural plant culture-medium that can be used in food and is designed according to different efficacy of different products by multi-stage solid-liquid complex fermentation technology. The functional directions of the product series involved are: immune function damage repair, intestinal villi damage repair, sperm development machinery damage repair, ovarian function damage repair, liver function damage repair, sleep disorder function damage repair, etc.Previous studies have shown that "KB-120" has good clinical effects on improving the number and function of male germ cells.Luanbao "KB-120" is a compound plant health drink specially for women. This study intends to give "KB-120" small molecule nutrients as nutritional supplement intervention in female patients with ovarian dysfunction, and observe its influence on endocrine function, ovarian reserve function and fertility in patients with ovarian dysfunction.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: "KB-120" small molecular nutrient and vitamin E
  • Dietary Supplement: Vitamin E
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve
Anticipated Study Start Date :
Oct 15, 2023
Anticipated Primary Completion Date :
Feb 5, 2024
Anticipated Study Completion Date :
Jul 5, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: experimental group

"KB-120" small molecule nutrients, taken orally once a day in one bag (30ml), and vitamin E100mg taken orally 2 times a day for a total of 3 menstrual cycles

Dietary Supplement: "KB-120" small molecular nutrient and vitamin E
The experimental group was given oral "KB-120" small molecular nutrients, once a day, once a bag (30ml), and vitamin E100mg orally twice a day for a total of 3 menstrual cycles

Dietary Supplement: Vitamin E
Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles

Active Comparator: control group

Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles

Dietary Supplement: Vitamin E
Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles

Outcome Measures

Primary Outcome Measures

  1. Concentration of serum FSH 1 [on the 3rd day of the 2nd menstruation(each cycle is 23-30 days)]

    Blood samples were collected on the 3rd day of the 2nd menstruation

  2. Concentration of serum FSH 2 [on the 3rd day of the 4th menstruation(each cycle is 23-30 days)]

    Blood samples were collected on the 3rd day of the 4th menstruation

  3. Concentration of serum AMH 1 [on the 3rd day of the 2nd menstruation(each cycle is 23-30 days)]

    Blood samples were collected on the 3rd day of the 2nd menstruation

  4. Concentration of serum AMH 2 [on the 3rd day of the 4th menstruation(each cycle is 23-30 days)]

    Blood samples were collected on the 3rd day of the 4th menstruation

Secondary Outcome Measures

  1. The number of days of the menstrual cycle 1 [At the end of Cycle 1 (each cycle is 23-30 days)]

    The number of days of the menstrual cycle 1

  2. The number of days of the menstrual cycle 3 [At the end of Cycle 3(each cycle is 23-30 days)]

    The number of days of the menstrual cycle 3

  3. The size of dominant follicle and the number of days required for ovulation 1 [At the end of Cycle 1 (each cycle is 23-30 days)]

    The follicle development of patients was monitored by ultrasound during the 1st menstrual cycle, and the monitoring interval was determined according to the clinical experience of clinicians and the development of patients' follicles

  4. The size of dominant follicle and the number of days required for ovulation 2 [At the end of Cycle 3 (each cycle is 23-30 days)]

    The follicle development of patients was monitored by ultrasound during the 3rd menstrual cycle, and the monitoring interval was determined according to the clinical experience of clinicians and the development of patients' follicles

  5. pregnancy rate for women trying to get pregnant 1 [At the end of Cycle 1 (each cycle is 23-30 days)]

    pregnancy rate for women trying to get pregnant

  6. pregnancy rate for women trying to get pregnant 2 [At the end of Cycle 3 (each cycle is 23-30 days)]

    pregnancy rate for women trying to get pregnant

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients with low ovarian function: FSH ≥10IU/L or AMH ≤1.1ng/ml.

  2. The age at the time of signing the informed consent is 20-40 years old (including 20 and 40 years old) and has not been menopausal;

  3. Be willing to sign written informed consent and comply with the study protocol

Exclusion Criteria:
  1. Patients with severe anemia or malignant tumor; Lactation or pregnancy;

  2. Eating disorders or anorexia;

  3. Taking hormone drugs or participating in any other study.

  4. There are factors that researchers believe cannot be included in the study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Women's Hospital School Of Medicine Zhejiang University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Women's Hospital School Of Medicine Zhejiang University
ClinicalTrials.gov Identifier:
NCT06081257
Other Study ID Numbers:
  • IRB-20230158-R
First Posted:
Oct 13, 2023
Last Update Posted:
Oct 17, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2023